SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
Dermatological map could lead to new treatments
Fri January 22nd - A newly created skin cell map offers a “huge leap” in understanding of disease and could pave the way for potential drug treatments for painful skin diseases, British researchers say. More
Half a million doctors needed for cancer surgery
Fri January 22nd - The world will need half a million more doctors in the next 20 years, just to cope with growing demand for cancer surgery, according to a major new analysis. More
RECENT COMMENTS
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 04/08/2020 VICKY P ADAM wrote:
I would like to thank WORLD HERBS CLINIC for reve... on Medieval remedy for bacterial ...
On 29/07/2020 Amdre wrote:
When i read many blogs online about cure to HSV, a... on Medieval remedy for bacterial ...
On 14/07/2020 margret wrote:
I was diagnosed of ALS (amyotrophic lateral sclero... on Heart abnormalities revealed i...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
OUR CLIENTS
THIS WEEK'S STORIES
ENGLEMED HEALTH NEWS

Synthetic nanobody could fight SARS-CoV-2 virus

Thursday November 5th 2020

A synthetic nanobody could be used to help combat COVID-19, a new study has revealed.

It is believed that blocking three receptor binding domains (RBDs), which the SARS-CoV-2 virus hooks on to, could stop it from entering human cells.

The Christian Löw group at the European Molecular Biology Laboratory (eMBL) Hamburg, Germany, searched through the existing libraries to find synthetic nanobodies, called sybodies, that could block SARS-CoV-2 from infecting human cells.

They used the viral spike protein's RBDs as bait to select those sybodies that bind to them before testing the selected sybodies according to their stability, effectiveness, and the precision of binding.

They found that sybody 23 was particularly effective in blocking the RBDs.

Researchers in the Dmitri Svergun group at EMBL Hamburg carried out small-angle X-ray scattering n to analyse the binding of sybody 23 to the RBDs, while Martin Hällberg at the Centre for Structural Systems Biology (CSSB) and Karolinska Institutet, Sweden, used cryo-EM to determine the structure of the full SARS-CoV-2 spike that bound to sybody 23.

Normally, RBDs switch between the 'up' position, ready to bind ACE2, or in the 'down' position, when they become furled to hide from the human immune system.

The researchers found that the molecular structures revealed that sybody 23 binds RBDs in both 'up' and 'down' positions and blocks the areas where ACE2 would normally bind.

They believe the ability to block RBDs regardless of their position might explain why sybody 23 is so effective.

Ben Murrell and his team at Karolinska Institutet tested to see if sybody 23 can neutralise a virus by using a lentivirus that was modified to carry the SARS-CoV-2's spike protein on its surface.

They found that sybody 23 successfully disabled the modified virus in vitro, although further tests are needed to see if it could stop SARS-CoV-2 infection in the human body.

Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2. Nature Communications 4 November 2020

[abstract]

Tags: Europe | Flu & Viruses | Pharmaceuticals

Printer friendly page Printer friendly page

Comment on this article:

Name:
Email:
Comment:
<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)
CATEGORIES